OA

Oaktree Acquisition Corp. III Life Sciences

OACC·NASDAQ

$10.63

-0.19%
Financial ServicesShell Companies

Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$261.31M
EPS0.3000
P/E Ratio35.43
Earnings Date

Intrinsic Alpha Methodology

Thesis Lenses

Signal · Driver · Risk

Signal

High confidence

Valuation multiple is elevated (P/E 35.4).

Valuation inputs: P/E 35.4, earnings yield +2.8%, momentum -0.2%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE +3.7%, ROIC -0.6%).

Profitability stack: net margin 0.0%, ROE +3.7%, ROIC -0.6%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +4.1%, momentum -0.2%, net margin 0.0%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

o

Oaktree Acquisition Corp. III Life Sciences Market vs Earnings Trajectory

OACC · NASDAQ

Loading price and EPS data...

OA

Oaktree Acquisition Corp. III Life Sciences Fair Value Envelope

OACC · NASDAQ

Our analysis suggests that OACC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.63, this represents a potential HIDDEN relative to our calculated worth for Oaktree Acquisition Corp. III Life Sciences.

Intrinsic Value
Current Price: $10.63
3Y+454.0%
5Y+454.0%
10Y+454.0%

No Revenue Data

OACC has not reported any revenue values in the available annual periods.

3Y+273607.0%
5Y+273607.0%
10Y+273607.0%
3Y+235698.0%
5Y+235698.0%
10Y+235698.0%
3Y+235698.0%
5Y+235698.0%
10Y+235698.0%
3Y+4.0%
5Y+4.0%
10Y+4.0%
OA

Oaktree Acquisition Corp. III Life Sciences Profit Bridge

OACC · NASDAQ
Revenue0.00
Cost of Goods Sold (0.00)
Gross Profit0.00
Operating Expenses (1.20M)
Operating Income-1.20M
Interest Expense (0.00)
Other Income/Expense8.48M
Pretax Income7.29M
Income Tax (0.00)
Net Income7.29M
Net Income
7.29M

Profitability Analysis

No Gross Profit Margin Data

OACC has not reported any gross profit margin values in the available annual periods.

No Operating Profit Margin Data

OACC has not reported any operating profit margin values in the available annual periods.

No Net Profit Margin Data

OACC has not reported any net profit margin values in the available annual periods.

3.74%
Return on Equity
267171%
3Y+267171.0%
5Y+267171.0%
10Y+267171.0%
3.59%
Return on Assets
256229%
3Y+256229.0%
5Y+256229.0%
10Y+256229.0%
-0.59%
Return on Invested Capital
148000%
3Y+148000.0%
5Y+148000.0%
10Y+148000.0%
O

Oaktree Acquisition Corp. III Life Sciences Cash Conversion Engine

OACC · NASDAQ
Net Income7.29M
Depreciation & Amortization0.00
Stock-Based Compensation0.00
Change in Working Capital0.00
Others-7.71M
Capital Expenditures0.00
Free Cash Flow-422.08K

Cash Flow Quality Analysis

FCF Conversion Rate

-5.8%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

FCF Growth Trend

-235698.3%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$0.00

Neutral working capital impact. Changes in current assets and liabilities balanced out.

Cash Flow Quality Insight

Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.

o

Oaktree Acquisition Corp. III Life Sciences Funding & Solvency Profile

OACC · NASDAQ
Cash & Cash Equivalents1.28M
Net Receivables0.00
Inventory0.00
Other Current Assets139.27K
Total Current Assets1 M
Property, Plant & Equipment0.00
Goodwill & Intangible Assets0.00
Long-Term Investments0.00
Other Non-Current Assets203.41M
Total Non-Current Assets203 M
Total Assets
204.83M

Financial Health Analysis

Current Ratio

0.87x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Debt-to-Equity Ratio

0.04x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

-207947

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

1% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.

o

Oaktree Acquisition Corp. III Life Sciences Street Expectations Map

OACC · NASDAQ

No Target Data

No analyst price targets available for oacc.

o

Oaktree Acquisition Corp. III Life Sciences Insider Positioning

OACC · NASDAQ

During the last 12 months, there has been no insider trading activity reported for OACC.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Neutral

No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.

Insider Participation

No Activity

No insider trading activity reported from any insiders in the past year.

0.00%
Dividend Yield
3Y-
5Y-
10Y-
 

oacc Dividend History

OACC
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%